116 related articles for article (PubMed ID: 38584441)
1. Efficacy of Brolucizumab in Polyp Regression of Treatment-Naive Polypoidal Choroidal Vasculopathy and Its Effect on 1-Year Treatment Outcome.
Lee SH; Park HS; Han JW
Korean J Ophthalmol; 2024 Jun; 38(3):185-193. PubMed ID: 38584441
[TBL] [Abstract][Full Text] [Related]
2. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
[TBL] [Abstract][Full Text] [Related]
3. Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy.
Cho HJ; Baek JS; Lee DW; Kim CG; Kim JW
Korean J Ophthalmol; 2012 Jun; 26(3):157-62. PubMed ID: 22670070
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy.
Cho HJ; Kang KH; Yoon W; Lee J; Kim CG; Kim JW
J Ocul Pharmacol Ther; 2023 Nov; 39(9):653-660. PubMed ID: 37504966
[No Abstract] [Full Text] [Related]
5. Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy.
Jeong S; Sagong M
Br J Ophthalmol; 2017 Jun; 101(6):758-763. PubMed ID: 27597740
[TBL] [Abstract][Full Text] [Related]
6. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
Morimoto M; Matsumoto H; Mimura K; Akiyama H
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with polyp regression after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.
Cho HJ; Han SY; Kim HS; Lee TG; Kim JW
Jpn J Ophthalmol; 2015 Jan; 59(1):29-35. PubMed ID: 25373450
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
[TBL] [Abstract][Full Text] [Related]
9. Differences between young and elderly polypoidal choroidal vasculopathy patients with and without pachychoroid phenotypes.
Wang Y; Zhang W; Yang J; Zhao X; Meng L; Chen Y; Zhang X;
Graefes Arch Clin Exp Ophthalmol; 2024 Jun; 262(6):1765-1776. PubMed ID: 38231247
[TBL] [Abstract][Full Text] [Related]
10. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
[TBL] [Abstract][Full Text] [Related]
11. Association between the arm-to-choroidal circulation time and clinical profile in patients with polypoidal choroidal vasculopathy.
Mukai R; Itagaki K; Honjyo J; Tanaka K; Norikawa K; Sekiryu T
Jpn J Ophthalmol; 2024 May; 68(3):211-215. PubMed ID: 38609716
[TBL] [Abstract][Full Text] [Related]
12. DIFFERENCE BETWEEN PACHYCHOROID AND NONPACHYCHOROID POLYPOIDAL CHOROIDAL VASCULOPATHY AND THEIR RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Chang YC; Cheng CK
Retina; 2020 Jul; 40(7):1403-1411. PubMed ID: 31181038
[TBL] [Abstract][Full Text] [Related]
13. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Baek JS; Lee DW; Cho SW; Kim CG; Kim JW
Retina; 2013; 33(10):2126-32. PubMed ID: 23609123
[TBL] [Abstract][Full Text] [Related]
14. Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathy.
Fukuda Y; Sakurada Y; Matsubara M; Kotoda Y; Kasai Y; Sugiyama A; Kashiwagi K
Jpn J Ophthalmol; 2023 Jul; 67(4):402-409. PubMed ID: 37289296
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
Lim TH; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Lee WK; Cheung CMG; Ngah NF; Patalauskaite R; Margaron P; Koh A;
JAMA Ophthalmol; 2020 Sep; 138(9):935-942. PubMed ID: 32672800
[TBL] [Abstract][Full Text] [Related]
16. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2021 Mar; 11(1):6759. PubMed ID: 33762600
[TBL] [Abstract][Full Text] [Related]
17. Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy.
Singh SR; Sahoo NK; Goud NR; Chhablani J
Indian J Ophthalmol; 2019 Jul; 67(7):1114-1118. PubMed ID: 31238423
[TBL] [Abstract][Full Text] [Related]
18. Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports.
Iesato Y; Tanaka M; Murata M; Kitahara J; Hirano T; Kurenuma T; Yoshida N; Murata T
BMC Ophthalmol; 2018 Nov; 18(1):284. PubMed ID: 30390650
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
Lee JE; Shin JP; Kim HW; Chang W; Kim YC; Lee SJ; Chung IY; Lee JE;
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):493-502. PubMed ID: 27628062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]